LifeMD, Inc. (LFMD) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
LifeMD, Inc. (LFMD) trades at $3.40 with AI Score 18/100 (Grade F). LifeMD, Inc. is a direct-to-patient telehealth company that connects consumers to healthcare professionals. Market cap: $164M, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: May 9, 2026LFMD stock analysis for 2026: Analysts have set a consensus price target of $10.00 for LifeMD, Inc., suggesting 194.1% upside from the current price of $3.40. The AI MoonshotScore is 18/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
LFMD: 2/3 scored disciplines lean bearish. Dominant signal: Financial Safety weak.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
LifeMD, Inc. (LFMD) Healthcare & Pipeline Overview
LifeMD, Inc. is a telehealth company providing direct-to-patient virtual care and prescription medications across various specialties, including men's sexual health, dermatology, and primary care. The company leverages e-commerce platforms and third-party channels to reach consumers seeking convenient and personalized healthcare solutions.
What Is the Investment Thesis for LFMD?
LifeMD, Inc. presents a compelling investment thesis centered on its direct-to-patient telehealth model and diverse service offerings. With a gross margin of 86.7%, the company demonstrates strong pricing power. Growth catalysts include expanding its telehealth platforms, increasing subscription-based primary care adoption, and scaling its dermatology and skincare brand, Nava MD. However, the company's negative profit margin of -7.8% and a beta of 1.77 indicate financial risks and market volatility. Successful execution of its growth strategies and achieving profitability are crucial for long-term value creation.
Based on FMP financials and quantitative analysis
LFMD Key Highlights
LifeMD operates as a direct-to-patient telehealth company, providing virtual medical treatment and prescription medications.
- The company's gross margin stands at 86.7%, reflecting efficient cost management and strong pricing strategies.
- LifeMD offers a range of telehealth brands, including ShapiroMD for hair loss, RexMD for men's health, and LifeMD Primary Care for virtual primary care.
- The company's market capitalization is $0.18 billion, indicating its current valuation in the market.
- LifeMD employs 304 individuals, reflecting its operational scale and workforce size.
Who Are LFMD's Competitors?
LFMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| TDOC Teladoc Health, Inc. | $6.49 | -2.55% | $1.18B | — |
| AMWL American Well Corporation (AMWL) | $11.79 | -4.92% | $201M | — |
| CVS CVS Health Corporation | $93.65 | -1.33% | $119B | 70 |
| HITI High Tide Inc. | $2.42 | -1.42% | $213M | 47 |
| LFLY Leafly Holdings, Inc. | $37.00 | +0.00% | $115M | 50 |
| BJTRF Beijing Tong Ren Tang Chinese Medicine Company Limited | $0.65 | +0.00% | $543M | 55 |
| MYCOF Noveris Health Sciences Inc. | $0.73 | +0.00% | $42.7M | 48 |
| YI 111, Inc. | $3.44 | -1.99% | $30.1M | 44 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LFMD's Key Strengths?
Diverse portfolio of telehealth brands catering to various health needs.
- Direct-to-patient model that provides greater control over the customer experience.
- Strong gross margin of 86.7%.
- Established presence in the rapidly growing telehealth market.
What Are LFMD's Weaknesses?
Negative profit margin of -7.8%.
- High beta of 1.77, indicating market volatility.
- Reliance on customer acquisition through marketing and advertising.
- Competition from larger, more established telehealth providers.
What Could Drive LFMD Stock Higher?
LFMD catalyst: Expansion of LifeMD Primary Care to new states, increasing access to virtual primary care services.
- Continued growth in subscription revenue from LifeMD Primary Care and other telehealth platforms.
- Strategic partnerships with healthcare providers and insurance companies to expand market reach.
- Launch of new products and services within the ShapiroMD and Nava MD brands.
- Integration of AI and machine learning to enhance the efficiency and effectiveness of LifeMD's telehealth platform.
What Are the Key Risks for LFMD?
Financial-distress signal — its Altman Z-Score of -1.71 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Increasing competition in the telehealth market could put pressure on pricing and margins.
- Regulatory changes and uncertainty surrounding telehealth services could impact LifeMD's business model.
- Data security breaches and privacy concerns could damage LifeMD's reputation and erode customer trust.
- Reliance on customer acquisition through marketing and advertising could become more expensive and less effective.
- Inability to achieve profitability could limit LifeMD's ability to invest in growth initiatives.
What Are the Growth Opportunities for LFMD?
- Expansion of LifeMD Primary Care: LifeMD can capitalize on the growing demand for virtual primary care services by expanding its LifeMD Primary Care platform. The virtual primary care market is projected to reach $265 billion by 2030, offering a substantial growth opportunity. By enhancing its platform with additional features, such as remote patient monitoring and chronic disease management programs, LifeMD can attract more subscribers and increase recurring revenue. Timeline: Ongoing.
- Scaling Nava MD: The female-oriented tele-dermatology and skincare market is experiencing rapid growth, driven by increasing consumer interest in personalized skincare solutions. LifeMD can leverage its Nava MD brand to capture a larger share of this market by expanding its product offerings, enhancing its virtual consultation services, and increasing its marketing efforts. The global skincare market is expected to reach $180 billion by 2027. Timeline: Ongoing.
- Strategic Partnerships: LifeMD can pursue strategic partnerships with healthcare providers, insurance companies, and employers to expand its reach and access new customer segments. Collaborating with established healthcare players can provide LifeMD with credibility, access to patient networks, and potential reimbursement opportunities. Timeline: Upcoming.
- Geographic Expansion: LifeMD can expand its services to new geographic markets, both domestically and internationally. The global telehealth market is projected to reach $550 billion by 2030, offering significant growth opportunities in various regions. Adapting its services to meet the specific needs and regulatory requirements of each market will be crucial for success. Timeline: Upcoming.
- Integration of AI and Machine Learning: LifeMD can leverage artificial intelligence (AI) and machine learning (ML) technologies to enhance its services, improve patient outcomes, and streamline operations. AI-powered diagnostic tools, personalized treatment recommendations, and automated customer support can improve the efficiency and effectiveness of LifeMD's telehealth platform. Timeline: Ongoing.
What Are LFMD's Competitive Advantages?
- Established telehealth platforms with recognized brands (ShapiroMD, RexMD, LifeMD Primary Care).
- Direct-to-patient model that eliminates intermediaries and provides greater control over the customer experience.
- Proprietary technology and data analytics capabilities that enable personalized treatment recommendations.
- Strong focus on customer acquisition and retention through targeted marketing and customer support.
What Does LFMD Do?
LifeMD, Inc., founded in 1994 and formerly known as Conversion Labs, Inc. until February 2021, operates as a direct-to-patient telehealth company headquartered in New York City. The company connects consumers with healthcare professionals, offering virtual care across various indications, including concierge care, men's sexual health, dermatology, and primary care. LifeMD's portfolio includes several telehealth brands: ShapiroMD, which focuses on hair loss solutions for men and women; RexMD, catering to men's health needs; LifeMD Primary Care, a subscription-based virtual primary care platform; Cleared, specializing in allergy, asthma, and immunology treatments; and Nava MD, a female-oriented tele-dermatology and skincare brand. In addition to its telehealth services, LifeMD offers PDFSimpli, an online software-as-a-service platform for creating, editing, and managing PDF documents. The company distributes its products and services directly to consumers through its e-commerce platforms and via third-party partner channels, emphasizing accessibility and convenience in healthcare delivery.
What Products and Services Does LFMD Offer?
- Connects consumers with healthcare professionals through telehealth platforms.
- Provides virtual medical treatment for various indications, including men's sexual health, dermatology, and primary care.
- Offers prescription medications and over-the-counter products through its telehealth brands.
- Operates ShapiroMD, a telehealth platform for hair loss solutions.
- Manages RexMD, a telehealth brand catering to men's health needs.
- Runs LifeMD Primary Care, a subscription-based virtual primary care platform.
- Provides personalized treatments for allergy, asthma, and immunology through Cleared.
- Offers tele-dermatology and skincare services through Nava MD.
How Does LFMD Make Money?
- Generates revenue through virtual consultations and treatment services.
- Sells prescription medications and over-the-counter products directly to consumers.
- Offers subscription-based virtual primary care services.
- Partners with e-commerce platforms and third-party channels for distribution.
What Industry Does LFMD Operate In?
LifeMD operates within the rapidly expanding telehealth industry, which has experienced significant growth due to increased demand for remote healthcare services. The market is characterized by increasing adoption of virtual consultations, remote patient monitoring, and digital therapeutics. LifeMD competes with other telehealth providers, traditional healthcare systems, and direct-to-consumer healthcare brands. The company's success depends on its ability to differentiate its services, maintain regulatory compliance, and effectively market its offerings to consumers.
Who Are LFMD's Key Customers?
- Consumers seeking convenient and accessible healthcare solutions.
- Individuals with specific health concerns, such as hair loss, men's health issues, and dermatological conditions.
- Patients seeking virtual primary care services.
- Individuals looking for personalized treatments for allergy, asthma, and immunology.
LifeMD, Inc. Financial Trajectory
LifeMD, Inc. (LFMD) reported $47.3M in revenue for Q2 2026, a decline of 5.7% compared to the prior quarter. The company recorded a net loss of $7.1M, with diluted EPS of $-0.16. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, LFMD averaged $-0.13 in diluted EPS.
Company Profile
LifeMD, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Justin Schreiber. LFMD has traded publicly since 2008.
How LifeMD, Inc. Is Valued
LifeMD, Inc. carries a market capitalization of $164M, placing it in the micro-cap category. Relative to its peer group, LFMD's quantitative score of 18/100 is below the peer average of 56/100.
Key Financial Metrics
Return on assets is -35.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.90 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -12.9%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
LifeMD, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.71 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
LifeMD, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 48.4% below estimates on average.
Forward Outlook
Wall Street analysts project LifeMD, Inc. revenue of about $217.2M for fiscal 2026, with EPS near $-0.43. The estimate reflects 6 contributing analysts.
LFMD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Diverse portfolio of telehealth brands catering to various health needs.
- Direct-to-patient model that provides greater control over the customer experience.
- Strong gross margin of 86.7%.
- Established presence in the rapidly growing telehealth market.
Bear Case
- Negative profit margin of -7.8%.
- High beta of 1.77, indicating market volatility.
- Reliance on customer acquisition through marketing and advertising.
- Competition from larger, more established telehealth providers.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $47M | -$7M | -$0.16 |
| Q1 2026 | $50M | -$9M | -$0.20 |
| Q4 2025 | $47M | -$1M | -$0.05 |
| Q3 2025 | $60M | -$4M | -$0.10 |
Based on FMP financials and quantitative analysis
LFMD Latest News
-
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
globenewswire.com · Jun 23, 2026
-
LifeMD To Launch Program For XYOSTED Injection
benzinga · Jun 22, 2026
-
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
globenewswire.com · Jun 22, 2026
-
Earnings Scheduled For May 6, 2025
benzinga · May 6, 2025
LFMD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LFMD.
Price Targets
Consensus target: $10.00
LFMD MoonshotScore
What does this score mean?
The MoonshotScore rates LFMD 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest News
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
LifeMD To Launch Program For XYOSTED Injection
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
Earnings Scheduled For May 6, 2025
Leadership: Justin Schreiber
CEO
Justin Schreiber serves as the CEO of LifeMD, Inc., leading the company's strategic direction and growth initiatives. His background includes extensive experience in digital marketing, e-commerce, and healthcare technology. Prior to joining LifeMD, Schreiber held leadership positions at various technology companies, where he focused on driving revenue growth and improving customer engagement. He has a proven track record of building and scaling successful businesses in the digital health space.
Track Record: Since becoming CEO, Justin Schreiber has overseen LifeMD's transition to a direct-to-patient telehealth company, expanding its service offerings and increasing its customer base. He has also led the acquisition and integration of several telehealth brands, including ShapiroMD, RexMD, and Nava MD. Under his leadership, LifeMD has achieved significant revenue growth and established a strong presence in the telehealth market.
What Investors Ask About LifeMD, Inc. (LFMD) — Healthcare
What does the AI Score mean for LFMD?
LFMD holds an AI Score of 18/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. LifeMD, Inc. is a direct-to-patient telehealth company that connects consumers to healthcare professionals. It offers virtual medical treatment and prescription medications across various …
What does LifeMD, Inc. do?
LifeMD, Inc. operates as a direct-to-patient telehealth company, connecting consumers with healthcare professionals for virtual medical treatment and prescription medications. The company offers a range of telehealth brands, including ShapiroMD for hair loss, RexMD for men's health, LifeMD Primary Care for virtual primary care, Cleared for allergy and asthma, and Nava MD for tele-dermatology.
What do analysts say about LFMD stock?
Analyst coverage of LifeMD, Inc. (LFMD) is limited, but the general sentiment reflects cautious optimism regarding the company's growth potential in the telehealth market. Key valuation metrics, such as price-to-sales ratio, are considered in relation to the company's revenue growth rate and gross margin. Analysts are closely monitoring LifeMD's ability to achieve profitability and manage its operating expenses.
What are the main risks for LFMD?
LifeMD, Inc. faces several risks, including increasing competition in the telehealth market, regulatory uncertainty surrounding telehealth services, and potential data security breaches. The company's reliance on customer acquisition through marketing and advertising exposes it to the risk of rising customer acquisition costs and declining marketing effectiveness. Additionally, LifeMD's negative profit margin and high beta indicate financial risks and market volatility. Successfully managing these risks is crucial for LifeMD's long-term success.
How does LifeMD, Inc. navigate regulatory approval processes?
LifeMD, Inc. navigates regulatory approval processes by ensuring compliance with federal and state regulations governing telehealth services, prescription drug sales, and data privacy. The company works with licensed healthcare professionals who adhere to professional standards and ethical guidelines. LifeMD also implements robust data security measures to protect patient information and comply with HIPAA regulations.
How does LifeMD, Inc. differentiate itself from competitors in the telehealth market?
LifeMD, Inc. differentiates itself from competitors in the telehealth market through its diverse portfolio of telehealth brands, its direct-to-patient model, and its focus on personalized treatment recommendations. The company's ShapiroMD brand offers specialized hair loss solutions, while RexMD caters to men's health needs. LifeMD Primary Care provides comprehensive virtual primary care services.
What are the key factors to evaluate for LFMD?
LifeMD, Inc. (LFMD) holds an AI score of 18/100 (low). Analysts target $10.00 (+194%). presents a compelling investment thesis centered on its direct-to-patient telehealth model and diverse service offerings. Not financial advice.
How frequently does LFMD data refresh on this page?
LFMD's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven LFMD's recent stock price performance?
LifeMD, Inc. (LFMD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse portfolio of telehealth brands catering to various health needs. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are based on the most recent available data.